Kihlberg, Jan

Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates

Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology

Computational Drug Discovery MethodsDrug Solubulity and Delivery Systems

Cited by 835

How Big Is Too Big for Cell Permeability?

Matsson, P., & Kihlberg, J. (2017) · Journal of Medicinal Chemistry

Computational Drug Discovery MethodsChemical Synthesis and Analysis

Cited by 303

Solution Conformations Shed Light on PROTAC Cell Permeability

Atilaw, Y., Poongavanam, V., Svensson Nilsson, C., Nguyen, D., Giese, A., Meibom, D., Erdelyi, M., & Kihlberg, J. (2021) · ACS Medicinal Chemistry Letters

Protein Degradation and InhibitorsChemical Synthesis and Analysis

Cited by 208

Immunization with glycosylated Kb‐binding peptides generates carbohydrate‐specific, unrestricted cytotoxic T cells

Abdel‐Motal, U. M., Berg, L., Rosén, A., Bengtsson, M., Thorpe, C. J., Kihlberg, J., Dahmén, J., Magnusson, G., Karlsson, K., & Jondal, M. (1996) · European Journal of Immunology

Immunotherapy and Immune ResponsesT-cell and B-cell Immunology

Cited by 85

PROTAC Cell Permeability and Oral Bioavailability: A Journey Into Uncharted Territory

Poongavanam, V., & Kihlberg, J. (2022) · Future Medicinal Chemistry

Protein Degradation and InhibitorsRNA Interference and Gene Delivery

Cited by 72